Altimmune, Inc. ALT
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Altimmune, Inc. (ALT) is a healthcare company listed in the US with a market value of about $320M. In fiscal year 2025 it had revenue of $41000 and net income of -$88M, a net margin of -214861.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -65% a year, a 5-year average ROIC of -45%.
About Altimmune
Altimmune is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2016 to $41000 in 2025, a decline of about 38.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 88% over three years (dilution for shareholders). It spends 162029% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41000 | $20000 | $426000 | -$68000 | $4M | $8M | $6M | $10M | $11M | $3M |
| Net income | -$88M | -$95M | -$88M | -$85M | -$97M | -$49M | -$21M | -$39M | -$46M | -$11M |
| Free cash flow | -$68M | — | -$76M | -$63M | -$90M | -$35M | -$10M | -$10M | -$20M | -$6M |
| EPS (diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | $-1.60 | $-15.16 | $-118.91 | $87.47 |
| Net margin | -214900.0% | -475300.0% | -20762.2% | 124600.0% | -2201.6% | -599.2% | -353.7% | -379.2% | -432.3% | -342.6% |
| ROIC | -36.0% | -65.1% | -38.9% | -45.8% | -37.9% | -21.5% | -43.6% | -73.7% | -105.4% | -33.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $16.33, 893% above the current price; targets range from $11.00 to $26.00; the consensus rating is “Strong buy”; expected EPS is $-0.63 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Altimmune pay a dividend?
Not currently.
Is Altimmune a good stock to buy?
We do not give buy or sell advice. Altimmune scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.